Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in sickle cell disease
PACTR202203740886208Phase 2Not yet recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of mitapivat in sickle cell disease (SCD) (3 arms), sponsored by Agios Pharmaceuticals. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202203740886208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202203740886208.